0.4556
price down icon16.11%   -0.0875
after-market After Hours: .46 0.0044 +0.97%
loading
Cytomx Therapeutics Inc stock is traded at $0.4556, with a volume of 2.04M. It is down -16.11% in the last 24 hours and down -30.21% over the past month. CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$0.5431
Open:
$0.55
24h Volume:
2.04M
Relative Volume:
1.16
Market Cap:
$36.49M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-22.78
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
-27.48%
1M Performance:
-30.21%
6M Performance:
-60.38%
1Y Performance:
-77.88%
1-Day Range:
Value
$0.4505
$0.5529
1-Week Range:
Value
$0.4505
$0.6506
52-Week Range:
Value
$0.4505
$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
Name
Cytomx Therapeutics Inc
Name
Phone
650.515.3185
Name
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
Employee
121
Name
Twitter
@cytomxinc
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
CTMX's Discussions on Twitter

Compare CTMX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CTMX
Cytomx Therapeutics Inc
0.4556 36.49M 101.21M -569.00K -56.88M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-28-24 Upgrade Piper Sandler Neutral → Overweight
May-09-24 Upgrade Wedbush Neutral → Outperform
May-06-24 Upgrade Jefferies Hold → Buy
Apr-22-24 Upgrade JP Morgan Underweight → Neutral
Nov-14-22 Downgrade BMO Capital Markets Outperform → Market Perform
Jul-07-22 Downgrade Jefferies Buy → Hold
Jul-07-22 Downgrade Mizuho Buy → Neutral
Jul-07-22 Downgrade Piper Sandler Overweight → Neutral
Jul-07-22 Downgrade Wedbush Outperform → Neutral
Jun-24-22 Initiated BMO Capital Markets Outperform
Jan-18-22 Upgrade Barclays Underweight → Overweight
Nov-15-21 Initiated BTIG Research Buy
May-28-21 Downgrade Barclays Equal Weight → Underweight
Mar-29-21 Initiated JP Morgan Overweight
Mar-23-21 Upgrade Jefferies Hold → Buy
Sep-22-20 Downgrade Guggenheim Buy → Neutral
Jun-01-20 Downgrade Jefferies Buy → Hold
May-14-20 Reiterated H.C. Wainwright Buy
Mar-24-20 Upgrade Wedbush Neutral → Outperform
Mar-04-20 Initiated Barclays Equal Weight
Nov-20-19 Initiated Guggenheim Buy
Nov-11-19 Downgrade Wedbush Outperform → Neutral
Jun-13-19 Initiated Mizuho Buy
May-14-19 Initiated Cantor Fitzgerald Overweight
Mar-11-19 Initiated Barclays Overweight
Nov-26-18 Initiated Piper Jaffray Overweight
Oct-15-18 Initiated Goldman Neutral
Sep-13-18 Initiated H.C. Wainwright Buy
Jun-01-18 Initiated SunTrust Buy
Jan-05-18 Initiated Citigroup Buy
Sep-08-17 Initiated Wedbush Outperform
Mar-27-17 Initiated H.C. Wainwright Buy
Mar-02-17 Initiated Instinet Buy
Jan-03-17 Downgrade Oppenheimer Outperform → Perform
Nov-02-15 Initiated Oppenheimer Outperform
View All

Cytomx Therapeutics Inc Stock (CTMX) Latest News

pulisher
Apr 03, 2025

CytomX stock hits 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

CytomX stock hits 52-week low at $0.56 amid market challenges - Investing.com Australia

Apr 03, 2025
pulisher
Apr 02, 2025

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.02 - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Financial Metrics Check: CytomX Therapeutics Inc (CTMX)’s Ratios for Trailing Twelve Months - DWinneX

Apr 01, 2025
pulisher
Apr 01, 2025

CytomX Therapeutics (NASDAQ:CTMX) Downgraded by StockNews.com to Hold - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Virtu Financial LLC - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

StockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Hold - The AM Reporter

Apr 01, 2025
pulisher
Mar 26, 2025

CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - MSN

Mar 26, 2025
pulisher
Mar 23, 2025

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - MSN

Mar 23, 2025
pulisher
Mar 21, 2025

CytomX therapeutics general counsel sells $6,111 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 20, 2025

Top Executives Cash Out: CytomX Therapeutics Stock Transactions Unveiled! - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics CEO sells $22,555 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics CEO sells $22,555 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX therapeutics general counsel sells $6,111 in stock By Investing.com - Investing.com UK

Mar 20, 2025
pulisher
Mar 13, 2025

CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

CytomX at Barclays Healthcare: Probody Platform Progress By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

CytomX at Barclays Healthcare: Probody Platform Progress - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India

Mar 12, 2025
pulisher
Mar 11, 2025

Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News

Mar 11, 2025
pulisher
Mar 11, 2025

CytomX Therapeutics (NASDAQ:CTMX) Upgraded by StockNews.com to “Buy” Rating - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

What Are You Thinking About Investing In CytomX Therapeutics Inc (NASDAQ: CTMX) Stock? - stocksregister.com

Mar 10, 2025
pulisher
Mar 10, 2025

CytomX Therapeutics’ (CTMX) Outperform Rating Reiterated at Wedbush - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Brokerages - Armenian Reporter

Mar 10, 2025
pulisher
Mar 10, 2025

CytomX Therapeutics’ (CTMX) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025
pulisher
Mar 08, 2025

CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 08, 2025
pulisher
Mar 08, 2025

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now - Insider Monkey

Mar 07, 2025
pulisher
Mar 07, 2025

Deal Watch: Amgen, CytomX Pull Back On Part Of T-Cell Engager Collaboration - Citeline News & Insights

Mar 07, 2025
pulisher
Mar 07, 2025

Cautious Outlook for CytomX Therapeutics Amid Pipeline Challenges and Strategic Setbacks - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX stock plunges to 52-week low, touches $0.6 By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - The Manila Times

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics Inc earnings beat by $0.43, revenue topped estimates - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Mar 07, 2025
pulisher
Mar 06, 2025

CytomX Therapeutics Reports Strong 2024 Financial Results - TipRanks

Mar 06, 2025

Cytomx Therapeutics Inc Stock (CTMX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):